Skip to main content

CORRECTION article

Front. Immunol., 08 December 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1111230
This article is part of the Research Topic Combinational Immunotherapy of Cancer: Novel Targets, Mechanisms, and Strategies View all 85 articles

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer

This article is a correction to:

  1. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

    1. Read original article
Kang MiaoKang MiaoXiaotong ZhangXiaotong ZhangHanping WangHanping WangXiaoyan SiXiaoyan SiJun NiJun NiWei ZhongWei ZhongJing ZhaoJing ZhaoYan XuYan XuMinjiang ChenMinjiang ChenRuili PanRuili PanMengzhao Wang*&#x;Mengzhao Wang*†Li Zhang*&#x;Li Zhang*†
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

A Corrigendum on
Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non–small cell lung cancer

by Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, Zhao J, Xu Y, Chen M, Pan R, Wang M and Zhang L (2022) Front. Immunol. 13:912180. doi: 10.3389/fimmu.2022.912180

In the published article, there was an error in affiliation 1. Instead of “Department of Pulmonary and Critical Care Medicine, Peking Union Medical Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China”, it should be “Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: immune checkpoint inhibitors (ICIs), lymphocyte subsets, CD4+CD45RA− T cell, biomarker, CD8+CD38+ T cell

Citation: Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, Zhao J, Xu Y, Chen M, Pan R, Wang M and Zhang L (2022) Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer. Front. Immunol. 13:1111230. doi: 10.3389/fimmu.2022.1111230

Received: 29 November 2022; Accepted: 30 November 2022;
Published: 08 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Miao, Zhang, Wang, Si, Ni, Zhong, Zhao, Xu, Chen, Pan, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Li Zhang, zhanglipumch1026@sina.com; Mengzhao Wang, mengzhaowang@sina.com

†These authors share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.